# **Product** Data Sheet

## (-)-TK216

Cat. No.: HY-122903A CAS No.: 1903783-78-7 Molecular Formula:  $C_{19}H_{15}Cl_2NO_3$  Molecular Weight: 376.23

Target: DNA/RNA Synthesis

Pathway: Cell Cycle/DNA Damage

Storage: Powder -20°C 3 years

4°C 2 years In solvent -80°C 6 months

-20°C 1 month

Rotation (-)

#### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (265.79 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.6579 mL	13.2897 mL	26.5795 mL
	5 mM	0.5316 mL	2.6579 mL	5.3159 mL
	10 mM	0.2658 mL	1.3290 mL	2.6579 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility:  $\ge$  2.5 mg/mL (6.64 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description	(-)-TK216 is an enantiomer of TK216 (HY-122903). TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. (-)-TK216 has anti-cancer activity $^{[1][2]}$ .
In Vitro	(-)-TK216 (compound 14; for 3 days) has an IC $_{50}$ <5 $\mu$ M in SKES cells (Ewing Sarcoma cell line) $^{[2]}$ . (-)-TK216 has $T_{1/2}$ s of 27.7 mins, 2.8 mins, 23.1 mins and 40.8 mins for human, rat, mouse, dog liver microsomes $^{[2]}$ . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

(-)-TK216 (compound 14; 5 mg/kg for iv or 25 mg/kg for po) has  $T_{1/2}$ s of 0.8 hours and 3.1 hours, and AUCs of 4131 h•(ng/mL) and 13152 h•(ng/mL) for iv and po, respectively, in BALB/c mice or Sprague Dawley rats<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Spriano F, et al. The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clin Cancer Res. 2019 Aug 15;25(16):5167-5176.

[2]. Jean-Michael Vernier, et al. Indolinone compounds and uses thereof. WO2016057698A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA